PapersFlow Research Brief
Lung Cancer Diagnosis and Treatment
Research Guide
What is Lung Cancer Diagnosis and Treatment?
Lung cancer diagnosis and treatment encompasses screening methods like low-dose CT, targeted therapies such as EGFR inhibitors and PD-1 inhibitors, staging systems, and emerging AI-based imaging analysis to detect, classify, and manage lung cancer.
There are 124,030 works on lung cancer diagnosis and treatment. "Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening" (Aberle et al., 2011) demonstrated that low-dose CT screening reduces lung cancer mortality. "Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer" (Reck et al., 2016) showed pembrolizumab improves progression-free and overall survival in PD-L1-positive advanced NSCLC compared to chemotherapy.
Research Sub-Topics
Low-Dose CT Screening for Lung Cancer
This sub-topic evaluates the efficacy, overdiagnosis rates, and implementation of LDCT screening protocols in high-risk populations from trials like NLST. Researchers develop risk models, nodule management guidelines, and cost-effectiveness analyses.
PD-1/PD-L1 Checkpoint Inhibitors in NSCLC
Studies investigate pembrolizumab and related immunotherapies in PD-L1-positive advanced NSCLC, including biomarker selection and combination regimens. Research spans phase III trials, resistance mechanisms, and real-world outcomes.
EGFR Tyrosine Kinase Inhibitors in Lung Cancer
This area covers first- to third-generation TKIs like gefitinib, osimertinib for EGFR-mutant NSCLC, focusing on acquired resistance via T790M and C797S. Clinical trials evaluate sequencing, combinations, and liquid biopsy monitoring.
Radiomics and Radiogenomics in Lung Cancer
Researchers extract quantitative imaging features from CT/PET scans to predict tumor genomics, histology, and treatment response without biopsy. Machine learning integrates radiomics with clinical data for noninvasive phenotyping.
Lung Cancer TNM Staging Systems
This sub-topic develops and validates IASLC revisions to TNM classification for NSCLC and SCLC, incorporating imaging, pathology, and survival data. Studies assess staging accuracy across global cohorts and propose refinements.
Why It Matters
Low-dose CT screening reduces lung cancer mortality, as shown in the National Lung Screening Trial reported in "Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening" (Aberle et al., 2011) with 10,599 citations. Pembrolizumab provides significantly longer survival with fewer adverse events than chemotherapy in PD-L1-positive NSCLC patients, per "Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer" (Reck et al., 2016). Gefitinib outperforms carboplatin-paclitaxel in EGFR-mutated pulmonary adenocarcinoma among East Asian nonsmokers, according to "Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma" (Mok et al., 2009). Osimertinib shows superior efficacy to standard EGFR-TKIs in first-line treatment of EGFR-mutated advanced NSCLC, as in "Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer" (Soria et al., 2017). These advances enable precision medicine, improving outcomes in high-risk populations and specific molecular subtypes.
Reading Guide
Where to Start
"Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening" (Aberle et al., 2011) first, as it provides foundational evidence for screening efficacy from the landmark National Lung Screening Trial.
Key Papers Explained
"Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening" (Aberle et al., 2011) establishes screening benefits. "Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma" (Mok et al., 2009) introduces targeted therapy superiority in EGFR-mutated cases. "Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer" (Reck et al., 2016) and "Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer" (Soria et al., 2017) build on this with immunotherapy and advanced TKIs. Staging evolves from "Revisions in the International System for Staging Lung Cancer" (Mountain, 1997) to "The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer" (Goldstraw et al., 2016).
Paper Timeline
Most-cited paper highlighted in red. Papers ordered chronologically.
Advanced Directions
Recent preprints explore cell-free RNA for diagnosis and monitoring, immunotherapy advances for 2025, computer-aided diagnosis with multimodal CT/PET fusion and interpretable AI, and treatments for advanced NSCLC resistance. News highlights LUNGevity and LCRF grants up to $1.65 million in 2025 for detection, resistance, and recurrence research.
Papers at a Glance
In the News
LUNGevity Now Accepting Research Grant Applications to ...
WASHINGTON,Jan. 15, 2026/PRNewswire/ -- LUNGevity Foundation, the nation's leading lung cancer–focused nonprofit organization, is now accepting applications for their 2026 research grants. These co...
LUNGevity and Rising Tide Foundation Issue RFA Tackling Lung Cancer's Toughest Challenges: Drug Resistance and Cancer Recurrence
This strategic initiative, called**RTFCCR/LUNGevity Award for Overcoming Treatment Resistance and Technology for Detection of Recurrence of Lung Cancer,**will provide up to $1,000,000 per project o...
LCRF announces additional 2025 Scientific Research ...
LCRF’s Leading-Edge Research Grant in Lung Cancer funds innovative research focused on the diagnosis, treatment, and cure of lung cancer. The LCRF Research Grant on Overcoming Resistance in Lung Ca...
LUNGevity Foundation Invests $1.2 Million to Fuel Next ...
LUNGevity Foundation announced $1.2 million in research awards that are designed to strengthen the lung cancer workforce and accelerate progress across the lung cancer continuum—from early detectio...
LCRF announces 2025 Scientific Research Grant Awards
The Lung Cancer Research Foundation® (LCRF) awarded its annual 2025 Scientific Grant Program awards, funding another $1.65 million in new research. This year’s grant cycle includes 11 awards in the...
Code & Tools
This project demonstrates a hybrid deep learning approach for the classification of lung cancer from CT scan images. It leverages a UNet-style diff...
Level 2 Logic Specification for Colorectal Cancer Screening Clinical Decision Support cancerscreeningcds.github.io/CDC-Colorectal-Cancer-Screening...
## About This work aims to construct Deep Learning (DL) and Machine Learning (ML) models for survival analysis, therapy outcome prediction and EGF...
The objective of "Artificial Intelligence-based Automated Lung Cancer Diagnosis" is to develop an AI system that can accurately analyze medical ima...
## Technologies Used This project is built using Python and the following technologies:
Recent Preprints
Clinical Lung Cancer: Home Page
_Clinical Lung Cancer_ is a peer-reviewed bimonthly journal that publishes original articles describing various aspects of clinical and translational research of **lung cancer**. _Clinical Lung Can...
Lung Cancer Diagnosis and Treatment Through Cell-free ...
Despite advances in treatment modalities, the complex nature of lung cancer, characterized by its molecular heterogeneity and resistance mechanisms, underscores the need for innovative approaches. ...
Lung cancer immunotherapy in 2025: where we stand and what comes next?
Lung cancer continues to be the leading cause of cancer-related mortality worldwide, accounting for more deaths than breast, colorectal, and prostate cancers combined. Over the past decade, the int...
Treatment of advanced‑stage non‑small cell lung cancer: Current progress and a glimpse into the future (Review) - PubMed
Before the twentieth century, patients with advanced lung cancer had limited treatment options and chemotherapy was the primary form of treatment, with an overall survival often <0.5 years. However...
Research progress in computer-aided diagnosis systems ...
Lung cancer remains the top cause of cancer death, demanding consistent decisions. This clinically oriented review synthesizes computer-aided diagnosis across classical imaging, machine learning, a...
Latest Developments
Recent developments in lung cancer diagnosis and treatment research as of February 2026 include a focus on early detection and personalized therapies, with promising advances such as immune-targeting vaccines like NOUS-209 for Lynch Syndrome patients (AACR), and the approval of new drugs like sevabertinib for non-squamous non-small cell lung cancer (FDA). Additionally, innovative approaches such as computer-aided diagnosis systems are progressing, and clinical trials are exploring targeted therapies and immunotherapies, including durvalumab for small cell lung cancer and neoadjuvant nivolumab plus chemotherapy (Nature, NEJM).
Sources
Frequently Asked Questions
What is the impact of low-dose CT screening on lung cancer mortality?
Low-dose CT screening reduces lung cancer mortality. "Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening" (Aberle et al., 2011) from the National Lung Screening Trial showed this effect. The trial was funded by the National Cancer Institute (NCT00047385).
How does pembrolizumab compare to chemotherapy in PD-L1-positive NSCLC?
Pembrolizumab yields longer progression-free and overall survival with fewer adverse events than platinum-based chemotherapy in advanced NSCLC with PD-L1 on at least 50% of tumor cells. This comes from "Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer" (Reck et al., 2016; KEYNOTE-024). The study was funded by Merck.
What role do EGFR mutations play in lung cancer treatment?
EGFR gene mutations predict better outcomes with gefitinib over carboplatin-paclitaxel in pulmonary adenocarcinoma among nonsmokers or former light smokers in East Asia. Osimertinib is superior to standard EGFR-TKIs in first-line treatment of EGFR-mutated advanced NSCLC. See "Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma" (Mok et al., 2009) and "Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer" (Soria et al., 2017).
How have lung cancer staging systems evolved?
"Revisions in the International System for Staging Lung Cancer" (Mountain, 1997) updated the TNM classification. "The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer" (Goldstraw et al., 2016) proposed further revisions for the eighth edition.
What is the role of CNNs in lung cancer diagnosis?
Deep convolutional neural networks enable computer-aided detection through data-driven image features from CT scans. "Deep Convolutional Neural Networks for Computer-Aided Detection: CNN Architectures, Dataset Characteristics and Transfer Learning" (Shin et al., 2016) highlights progress via large annotated datasets and transfer learning.
How does radiomics contribute to lung cancer phenotyping?
Quantitative radiomics decodes tumor phenotype noninvasively from imaging. "Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach" (Aerts et al., 2014) demonstrates this method's utility.
Open Research Questions
- ? How can screening protocols be optimized beyond low-dose CT to further reduce mortality in diverse populations?
- ? What combinations of immunotherapy and targeted therapies overcome resistance in PD-L1-positive and EGFR-mutated NSCLC?
- ? How can AI models like CNNs and radiomics improve early detection accuracy across heterogeneous lung cancer subtypes?
- ? What revisions to TNM staging best incorporate molecular and imaging biomarkers?
- ? How do EGFR mutation profiles evolve under osimertinib treatment to inform next-line therapies?
Recent Trends
Preprints from the last 6 months discuss cell-free RNA for lung cancer diagnosis and precision medicine, immunotherapy status for 2025 amid leading cancer mortality, and computer-aided diagnosis with multimodal imaging and interpretable AI. News reports LCRF 2025 grants totaling $1.65 million for diagnosis and resistance, LUNGevity $1.2 million awards across the continuum, and up to $1,000,000 RTFCCR/LUNGevity awards for resistance and recurrence detection.
Research Lung Cancer Diagnosis and Treatment with AI
PapersFlow provides specialized AI tools for your field researchers. Here are the most relevant for this topic:
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Deep Research Reports
Multi-source evidence synthesis with counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
AI Academic Writing
Write research papers with AI assistance and LaTeX support
Start Researching Lung Cancer Diagnosis and Treatment with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.